Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice

Journal of Medical Microbiology

Volumn 60, Issue 9, 2011, Pages 1248-1260

  Yam, Karen K ^a   Hugentobler, Felix ^a   Pouliot, Philippe ^a   Stern, Andrew M ^a   Lalande, Jean Daniel ^a   Matlashewski, Greg ^a   Olivier, Martin ^a,b   Cousineau, Benoit ^a  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A2 ANTIGEN; LEISHMANIA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BAGG ALBINO MOUSE; CELL WALL; CODON; CONTROLLED STUDY; CYTOPLASM; FEMALE; IMMUNE RESPONSE; INTRACELLULAR SPACE; LACTOCOCCUS LACTIS; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; INJECTIONS, SUBCUTANEOUS; LACTOCOCCUS LACTIS; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 80051744665     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.029959-0     Document Type: Article

References (46)

1. Abu-Dayyeh, I., Shio, M. T., Sato, S., Akira, S., Cousineau, B. & Olivier, M. (2008). Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl Trop Dis 2, e305.
2. Avall-Jääskeläinen, S., Kylä-Nikkilä, K., Kahala, M., Miikkulainen-Lahti, T. & Palva, A. (2002). Surface display of foreign epitopes on the Lactobacillus brevis S-layer. Appl Environ Microbiol 68, 5943-5951.
3. Bahey-El-Din, M., Casey, P. G., Griffin, B. T. & Gahan, C. G. (2008). Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. Vaccine 26, 5304-5314.
4. Beresford, T. P., Fitzsimons, N. A., Brennan, N. L. & Cogan, T. M. (2001). Recent advances in cheese microbiology. Int Dairy J 11, 259-274.
5. Bermúdez-Humarán, L. G., Cortes-Perez, N. G., Le Loir, Y., Alcocer-González, J.M., Tamez-Guerra, R. S., de Oca-Luna, R.M. & Langella, P. (2004). An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53, 427-433.
6. Buccato, S., Maione, D., Rinaudo, C. D., Volpini, G., Taddei, A. R., Rosini, R., Telford, J. L., Grandi, G. & Margarit, I. (2006). Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis 194, 331-340.
7. Casalta, E. & Montel, M. C. (2008). Safety assessment of dairy microorganisms: the Lactococcus genus. Int J Food Microbiol 126, 271-273.
8. Charest, H. & Matlashewski, G. (1994). Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol 14, 2975-2984.
9. Coelho, E. A., Tavares, C. A., Carvalho, F. A., Chaves, K. F., Teixeira, K. N., Rodrigues, R. C., Charest, H., Matlashewski, G., Gazzinelli, R. T. & Fernandes, A. P. (2003). Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71, 3988-3994.
10. Cortes-Perez, N. G., Bermúdez-Humarán, L. G., Le Loir, Y., Rodriguez-Padilla, C., Gruss, A., Saucedo-Cárdenas, O., Langella, P. & Montes-de-Oca-Luna, R. (2003). Mice immunization with live lactococci displaying a surface anchoredHPV-16 E7 oncoprotein. FEMS Microbiol Lett 229, 37-42.
11. Detmer, A. & Glenting, J. (2006). Live bacterial vaccines-a review and identification of potential hazards. Microb Cell Fact 5, 23.
12. Dieye, Y., Usai, S., Clier, F., Gruss, A. & Piard, J. C. (2001). Design of a protein-targeting system for lactic acid bacteria. J Bacteriol 183, 4157-4166.
13. FDA (1995). Aminopeptidase enzyme preparation derived from lactococcus lactis. Section CFR184.1985, Code of Federal Regulations, Title 21-Food and Drugs; Chapter I-Food and Drug Administration, Department of Health and Human Services; Subchapter B-Food for human consumption; Part 184-Direct food substances affirmed as Generally Recognized as Safe. MD, USA: US Food and Drug Administration.
14. Fernandes, A. P., Costa, M. M., Coelho, E. A., Michalick, M. S., de Freitas, E., Melo, M. N., Luiz Tafuri, W., Resende, D. de M., Hermont, V. & other authors (2008). Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26, 5888-5895.
15. Fuglsang, A. (2003). Lactic acid bacteria as prime candidates for codon optimization. Biochem Biophys Res Commun 312, 285-291.
16. Garin, Y. J., Meneceur, P., Pratlong, F., Dedet, J. P., Derouin, F. & Lorenzo, F. (2005). A2 gene of Old World cutaneous Leishmania is a single highly conserved functional gene. BMC Infect Dis 5, 18.
17. Ghedin, E., Zhang, W. W., Charest, H., Sundar, S., Kenney, R. T. & Matlashewski, G. (1997). Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4, 530-535.
18. Ghosh, A., Labrecque, S. & Matlashewski, G. (2001a). Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19, 3169-3178.
19. Ghosh, A., Zhang, W. W. & Matlashewski, G. (2001b). Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20, 59-66.
20. Grangette, C., Müller-Alouf, H., Hols, P., Goudercourt, D., Delcour, J., Turneer, M. & Mercenier, A. (2004). Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria. Infect Immun 72, 2731-2737.
21. Hanniffy, S. B., Carter, A. T., Hitchin, E. & Wells, J. M. (2007). Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 195, 185-193.
22. Kedzierski, L., Zhu, Y. & Handman, E. (2006). Leishmania vaccines: progress and problems. Parasitology 133 (Suppl.), S87-S112.
23. Khamesipour, A., Dowlati, Y., Asilian, A., Hashemi-Fesharki, R., Javadi, A., Noazin, S. & Modabber, F. (2005). Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23, 3642-3648.
24. Kuipers, O. P., Beerthuyzen, M. M., de Ruyter, P. G., Luesink, E. J. & de Vos, W. M. (1995). Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J Biol Chem 270, 27299-27304.
25. Kuipers, O. P., de Ruyter, P. G., Kleerebezem, M. & de Vos, W. M. (1998). Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 64, 15-21.
26. Le Loir, Y., Gruss, A., Ehrlich, S. D. & Langella, P. (1998). A nineresidue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 180, 1895-1903.
27. LeBlanc, D. J., Lee, L. N. & Abu-Al-Jaibat, A. (1992). Molecular, genetic, and functional analysis of the basic replicon of pVA380-1, a plasmid of oral streptococcal origin. Plasmid 28, 130-145.
28. Lee, P., Abdul-Wahid, A. & Faubert, G. M. (2009). Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii. Microbes Infect 11, 20-28.
29. Medina, M., Villena, J., Vintiñi, E., Hebert, E. M., Raya, R. & Alvarez, S. (2008). Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 76, 2696-2705.
30. Mierau, I. & Kleerebezem, M. (2005). 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68, 705-717.
31. Miyoshi, A., Poquet, I., Azevedo, V., Commissaire, J., Bermúdez-Humarán, L., Domakova, E., Le Loir, Y., Oliveira, S. C., Gruss, A. & Langella, P. (2002). Controlled production of stable heterologous proteins in Lactococcus lactis. Appl Environ Microbiol 68, 3141-3146.
32. Mizbani, A., Taheri, T., Zahedifard, F., Taslimi, Y., Azizi, H., Azadmanesh, K., Papadopoulou, B. & Rafati, S. (2009). Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28, 53-62.
33. Piard, J. C., Hautefort, I., Fischetti, V. A., Ehrlich, S. D., Fons, M. & Gruss, A. (1997). Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J Bacteriol 179, 3068-3072.
34. Resende, D. M., Caetano, B. C., Dutra, M. S., Penido, M. L., Abrantes, C. F., Verly, R. M., Resende, J. M., Piló-Veloso, D., Rezende, S. A. & Bruna-Romero, O. (2008). Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-c and cytolytic activity by CD8+ T cells. Vaccine 26, 4585-4593.
35. Ribeiro, L. A., Azevedo, V., Le Loir, Y., Oliveira, S. C., Dieye, Y., Piard, J. C., Gruss, A. & Langella, P. (2002). Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 68, 910-916.
36. Robinson, K., Chamberlain, L. M., Lopez, M. C., Rush, C. M., Marcotte, H., Le Page, R. W. & Wells, J. M. (2004). Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun 72, 2753-2761.
37. Roy, G., Dumas, C., Sereno, D., Wu, Y., Singh, A. K., Tremblay, M. J., Ouellette, M., Olivier, M. & Papadopoulou, B. (2000). Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110, 195-206.
38. Scavone, P., Miyoshi, A., Rial, A., Chabalgoity, A., Langella, P., Azevedo, V. & Zunino, P. (2007). Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 9, 821-828.
39. Stavnezer, J. (1996). Immunoglobulin class switching. Curr Opin Immunol 8, 199-205.
40. Steidler, L. (2003). Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 17, 861-876.
41. Tsang, R. S. W., Nielsen, K. H. & Johnson, W. M. (1995). Development of an indirect whole cell ELISA for the rapid identification of Salmonella. J Rapid Methods Autom Microbiol 4, 139-154.
42. Wells, J. M., Wilson, P. W. & Le Page, R. W. (1993). Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 74, 629-636.
43. Yam, K. K., Pouliot, P., N'diaye, M. M., Fournier, S., Olivier, M. & Cousineau, B. (2008). Innate inflammatory responses to the Grampositive bacterium Lactococcus lactis. Vaccine 26, 2689-2699.
44. Zhang, W.-W. & Matlashewski, G. (2001). Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 39, 935-948.
45. Zhang, W.-W., Charest, H., Ghedin, E. & Matlashewski, G. (1996). Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol 78, 79-90.
46. Zhang, W.-W., Mendez, S., Ghosh, A., Myler, P., Ivens, A., Clos, J., Sacks, D. L. & Matlashewski, G. (2003). Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem 278, 35508-35515.